EQS-Adhoc: HAEMATO AG: Termination of listing in the Open Market
|
EQS-Ad-hoc: HAEMATO AG / Key word(s): Delisting
Berlin, November 30, 2023: The Management Board of HAEMATO AG ("Company"; ISIN: DE000A289VV1/ Open Market / Basic Board) has decided today, November 30, 2023, with the approval of the Supervisory Board, to terminate the inclusion of the Company's shares in the Open Market (Basic Board) on the Frankfurt Stock Exchange pursuant to Section 30 of the General Terms and Conditions of Deutsche Börse AG for the Open Market on the Frankfurt Stock Exchange (so-called delisting). The Management Board of the company will therefore send a corresponding letter of termination to Deutsche Börse AG today, November 30, 2023.
Upon expiry of the notice period, which is three months and thus ends at the end of February 2024 at the latest, trading of the company's shares on the Open Market (Basic Board) of the Frankfurt Stock Exchange will be discontinued. Until the end of the three-month period, the company's shareholders will continue to have the opportunity to trade their shares on the Regulated Unofficial Market of the Frankfurt Stock Exchange. The company's shares will no longer be traded on another stock exchange at the company's instigation after their inclusion in the open market of the Frankfurt Stock Exchange has ended. About HAEMATO: HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on the trading of high-priced specialty pharmaceutical drugs (with a therapeutic emphasis on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". Further information can be found at https://haemato.de. Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.ag End of Inside Information
30-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | HAEMATO AG |
| Lilienthalstraße 5c | |
| 12529 Schönefeld | |
| Germany | |
| Phone: | +49 (0)30 897 30 86 70 |
| Fax: | +49 (0)30 897 30 86 79 |
| E-mail: | ir@haemato.ag |
| Internet: | www.haemato.ag |
| ISIN: | DE000A289VV1 |
| WKN: | A289VV |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1785693 |
| End of Announcement | EQS News Service |
|
|
1785693 30-Nov-2023 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 274,12 | 197,84 | 238,33 | 285,04 | 248,14 | 281,51 | 278,00 | |
| EBITDA1,2 | 9,96 | 1,90 | 3,31 | 12,64 | 9,66 | 11,50 | 11,10 | |
| EBITDA-Margin3 | 3,63 | 0,96 | 1,39 | 4,43 | 3,89 | 4,09 | 3,99 | |
| EBIT1,4 | 8,50 | -18,68 | 1,63 | 11,16 | 8,30 | 10,57 | 10,30 | |
| EBIT-Margin5 | 3,10 | -9,44 | 0,68 | 3,92 | 3,35 | 3,76 | 3,71 | |
| Net Profit (Loss)1 | 6,28 | -1,17 | -4,83 | 6,53 | 8,19 | 7,74 | 7,30 | |
| Net-Margin6 | 2,29 | -0,59 | -2,03 | 2,29 | 3,30 | 2,75 | 2,63 | |
| Cashflow1,7 | 0,56 | -2,76 | 14,67 | 14,05 | 19,73 | -3,32 | 8,40 | |
| Earnings per share8 | 2,70 | -0,50 | -1,02 | 1,35 | 1,57 | 1,48 | 1,40 | |
| Dividend per share8 | 1,00 | 0,00 | 0,00 | 1,10 | 1,20 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Harry Haseloff
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Haemato | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A289VV | DE000A289VV1 | AG | 55,43 Mio € | 05.12.2005 | - | 9F4M9H86+67 |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 6,75 | 14,80 | 0,46 | 5,83 | 0,37 | -16,70 | 0,20 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 1,20 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 16.07.2024 | 23.04.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -20,72% | -32,05% | -60,15% | -58,59% | +0,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
